局限期小细胞肺癌综合治疗疗效临床对比研究

目的探讨不同治疗模式下局限期小细胞肺癌患者的预后差异。方法回顾性分析48例局限期小细胞肺癌患者的临床资料,比较不同治疗模式下患者的中位生存期(median survival time,MST)、无进展生存期(progression free time,PFS)及不良反应发生率差异。结果综合治疗组(规范性化疗+同步放化疗+预防性脑放疗)患者MST显著优于不规范治疗组(P<0.05);规范性化疗组患者MST优于不规范性化疗组(P<0.05);同步放化疗组与序贯放化疗组患者MST比较差异无统计学意义(P=0.159);预防性脑放射组患者MST优于未行预防性脑放射组(P<0.05);综合治疗模式规范组患者PFS亦优于不规范组(P<0.05)。结论规范性综合治疗可显著提高局限期小细胞肺癌患者的MST和PFS。

Clinical contrast study on effect of multi-modality therapy for limited small-cell lung cancer

Objective To evaluate the difference of prognosis in limited small-cell lung cancer by different therapy modalities.Methods Forty-eight cases of limited small-cell lung cancer were retrospectivly analyzed,and the differences in median survival time（MST）,progression free time（PFS） and side effects incidence were compared.Results The MST of patients in multi-modality therapy group was better than those in non-standard therapy group（P0.05）.The MST of patients in standard chemotherapy group was also better than those in non-standard chemotherapy group（P0.05）.There was no significant difference between concurrent chemoradiotherapy group and sequence chemoradiotherapy group（P=0.159）.The MST of patients in prophylatic cranial irradiation group was better than those without prophylatic cranial irradiation（P0.05）.The PFS of patients in standard multi-modality therapy group was better than those in non-standard therapy group（P0.05）.Conclusion Standard multi-modality therapy may obviously improve the MST and PFS in patients with limited small-cell lung cancer.